OCS
OculisFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The cash runway into 2H 2029 gives Oculis time to keep Privosegtor PIONEER and Licaminlimab PREDICT-1 alive; the DME miss is painful, but the retained retinal-thickness signal suggests the program still showed pharmacologic activity.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Any delay or weak data in the remaining programs could re-open financing and dilution questions despite the current runway.
Momentum
3
Value
41
Sentiment
42
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.00 · Bull $21.00 · Bear $5.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $37.48
Why
Momentum3 · Δ7d +1.2
Value41 · Δ7d +0.0
Sentiment42 · Δ7d +6.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
3
26% active weight
Current posture
7d trendFlat
Δ7d
+1.2
Δ21d
+1.3
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
42
34% active weight
Current posture
7d trendImproving
Δ7d
+6.9
Δ21d
-3.1
Why this grade
Composite grade F. Momentum 3.0 / Value 41.1 / Sentiment 41.9
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$670.6M
Beta
0.14
Shares Out
57.17M
P/E (TTM) · Derived
-5.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.04
Rev YoY
-
EPS YoY
-18.4%
Gross Margin
-
Op Margin
-
Net Debt
-$265.95M
Current Ratio
5.18
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology